Avoro Capital Advisors Adds $34M in Revolution Medicines, Inc. ($RVMD)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Avoro Capital Advisors increased its position in Revolution Medicines, Inc. ($RVMD) by 8.04% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,344,444 shares of Revolution Medicines, Inc. after buying 174,444 shares during the quarter. Avoro Capital Advisors's holdings in Revolution Medicines, Inc. were worth $451.59 million as of its most recent filing.
Revolution Medicines, Inc. Stock Down 7.3%
Shares of Revolution Medicines, Inc. ($RVMD) traded around $192.62 on Saturday, down 7.3% for the day.
Revolution Medicines, Inc. Earnings
Analysts Set New Price Targets
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Get Revolution Medicines, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RVMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.